Biotest AG / Miscellaneous 28.10.2008 Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares Dreieich, the 28th of October 2008: The majority shareholder of Biotest AG, OGEL GmbH, informed the management board that OGEL GmbH is in discussions to dispose of parts of its share package. OGEL GmbH wishes to negotiate a transaction in close coordination with the management board of the company. According to OGEL GmbH, a positive decision has not yet been taken. If there is an event of change of control at Biotest AG, the acquiror will be under the obligation to launch a public takeover offer to all shareholders under the German Securities and Takeover Act. Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest AG, Dreieich, Germany, is a company that researches and manufactures pharmaceutical, biotherapeutic and diagnostic products and has specialised in immunology and haematology. In its Pharmaceutical segment, Biotest develops immunoglobulins, clotting factors and albumins based on human blood plasma. These are used for diseases of the immune system or haematopoietic system. In the Biotherapeutic segment, Biotest researches into the clinical development of monoclonal antibodies, including in the indications of rheumatoid arthritis and blood cancer. The Diagnostic segment spans reagents and immunological diagnostics which are used, for example, in blood transfusions and transplants. Biotest has around 1,850 employees worldwide and its shares are listed in the Stock Exchange's SDAX. Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de Dr. Michael Ramroth, Tel: +49 (0) 6103 801-819 Fax: +49 (0) 6103 801-347 e-mail: michael_ramroth@biotest.de WKN, ISIN ordinary share: 522720, DE0005227201 WKN, ISIN preference share: 522723, DE0005227235 Listed: Prime Standard/official trading Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart DGAP 28.10.2008 --------------------------------------------------------------------------- Language: English Issuer: Biotest AG Landsteinerstraße 5 63303 Dreieich Deutschland Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227201, DE0005227235 WKN: 522720, 522723 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Majority shareholder of Biotest AG in discussions about selling shares
| Source: EQS Group AG